The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Following on from an update from the company, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes